SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/268617"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/268617" > Growth Hormone Rese...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005242naa a2200841 4500
001oai:gup.ub.gu.se/268617
003SwePub
008240410s2018 | |||||||||||000 ||eng|
024a https://gup.ub.gu.se/publication/2686172 URI
024a https://doi.org/10.1530/ec-18-00472 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Johannsson, Gudmundur,d 1960u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition4 aut0 (Swepub:gu)xjgudn
2451 0a Growth Hormone Research Society perspective on biomarkers of GH action in children and adults
264 1b Bioscientifica,c 2018
520 a Objective: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults and in patients with acromegaly. Participants: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry. Evidence: Current literature was reviewed and expert opinion was utilized to establish the state of the art and identify current gaps and unmet needs. Consensus process: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process. Conclusions: The clinical endpoint in paediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH-deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly, normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
653 a GH
653 a IGF-I
653 a GH deficiency
653 a acromegaly
653 a surrogate end-points
653 a idiopathic short stature
653 a replacement therapy
653 a igf-i
653 a consensus statement
653 a deficient patients
653 a disease-activity
653 a turner
653 a syndrome
653 a serum
653 a pegvisomant
653 a Endocrinology & Metabolism
700a Bidlingmaier, M.4 aut
700a Biller, B. M. K.4 aut
700a Boguszewski, M.4 aut
700a Casanueva, F. F.4 aut
700a Chanson, P.4 aut
700a Clayton, P. E.4 aut
700a Choong, C. S.4 aut
700a Clemmons, D.4 aut
700a Dattani, M.4 aut
700a Frystyk, J.4 aut
700a Ho, K.4 aut
700a Hoffman, A. R.4 aut
700a Horikawa, R.4 aut
700a Juul, A.4 aut
700a Kopchick, J. J.4 aut
700a Luo, X. P.4 aut
700a Neggers, S.4 aut
700a Netchine, I.4 aut
700a Olsson, Daniel S,d 1983u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition4 aut0 (Swepub:gu)xolssd
700a Radovick, S.4 aut
700a Rosenfeld, R.4 aut
700a Ross, R. J.4 aut
700a Schilbach, K.4 aut
700a Solberg, P.4 aut
700a Strasburger, C.4 aut
700a Trainer, P.4 aut
700a Yuen, K. C. J.4 aut
700a Wickstrom, K.4 aut
700a Jorgensen, J. O. L.4 aut
710a Göteborgs universitetb Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition4 org
773t Endocrine Connectionsd : Bioscientificag 7:3, s. R126-R134q 7:3<R126-R134x 2049-3614
856u https://ec.bioscientifica.com/downloadpdf/journals/ec/7/3/EC-18-0047.pdf
8564 8u https://gup.ub.gu.se/publication/268617
8564 8u https://doi.org/10.1530/ec-18-0047

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy